1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?

A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy. A big name in COVID-19 care Much of Novavax's name recognition comes from the thick of the COVID-19 pandemic, as the company developed one of only four vaccines for the disease that got emergency use authorization from the U.S. Food and Drug Administration. That's a tough act to follow, and Novavax hasn't yet proven it can build out a long-term, sustainable business. So, like Smith, I can envision more downside ...